ClinicalTrials.Veeva

Menu

The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

F

Far Eastern Memorial Hospital

Status

Completed

Conditions

Sarcopenia
COPD Exacerbation

Treatments

Diagnostic Test: sarcopenia measurement

Study type

Observational

Funder types

Other

Identifiers

NCT04885933
FEMH-106099-E

Details and patient eligibility

About

Chronic obstructive pulmonary disease (COPD) is more prevalent and has more impact on health status because of progressive air pollution, tobacco smoking and aging society. The COPD prevalence investigation in 2013 by phone call showed at least 6% of the population with more than 40 years-old in Taiwan. It also was the 7th ranking of death causes in Taiwan then. Apart from chronic inflammation in lung and deteriorated lung function, it had extrapulmonary complications, such as cardiovascular problems, osteoporosis and muscle wasting. The concept of sarcopenia was proposed at first in 1989. It increases the risk of falls, disability and lowering life quality. Besides, it increased the mortality risk after admission from acute ward. Thereafter, sarcopenia is one of COPD co-morbidities, which should have great impacts of COPD. The studies showed sarcopenia reduced exercise capacities and worsening dyspnea scores. On the other hand, COPD exacerbation brings significant health burden. But there is limited data about the effect on sarcopenia on COPD exacerbation. We conducted a prospective observational study. We measured skeletal muscle mass and the strength of the used hand grip within 3 days of admission and before discharge. Mortality and exacerbation in one year are the primary end-points

Enrollment

43 patients

Sex

All

Ages

45+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria: Patients more than 45 years-old, were admitted due to COPD exacerbation.

COPD exacerbation criteria:

  1. acute worsening respiratory symptoms without any other causes, And
  2. Smoking more than 15 pack-years or the history of noxious gas exposure, And
  3. Spirometry reports suggests obstructive ventilatory defect (FEV1/FVC <0.7) or
  4. Attending physicians diagnose as COPD by clinical parameters if spirometry data are not available while enrolling.

Definite COPD exacerbation: fulfill 1、2、3 Probable COPD exacerbation: fulfill 1、2、4

Exclusion criteria:

  1. Significant fluid retention such as edema, pleural effusion or ascites,
  2. Patients with permanent pacemaker or implantable cardioverter defibrillator ,
  3. Morbid obesity with BMI >34

Trial design

43 participants in 1 patient group

COPD exacerbation
Treatment:
Diagnostic Test: sarcopenia measurement

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems